Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions
Whether you are on a lower dose that has stopped producing results or experiencing issues with your injection technique, dose-related factors deserve attention early in your troubleshooting process
However, additional therapies are required to circumvent rate-limiting steps within the signalling pathways of insulin action or to intervene directly in cellular glucose metabolism to reduce excess glucose production, improve peripheral glucose disposal and reduce glucotoxicity
The combination of increased medication levels and continued dose escalation creates a perfect storm of gastrointestinal distress
In contrast to other AOMs, which either suppress appetite or inhibit fat absorption [23], GLP-1RAs reduce body weight in a number of ways, decreasing appetite and hunger, and increasing satiety, resulting in reduced energy intake [24,25,26]